BioSpace News Archive

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced it will present at the Evercore ISI 2nd Annual HealthCONx Conference

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today announced that data from its Kv7 platform will be presented at the American Epilepsy Society’s (AES) 2019 Annual Meeting from December 6-10 in Baltimore.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company, today announced that its New Drug Application (NDA) for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted for filing by the U.S. Food and Drug Administration (FDA).

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that the IMV’s executive management team will participate in two upcoming investor conferences in December

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting ganaxolone data have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in Baltimore, Maryland on December 7 and 8, 2019.

Golden Meditech Holdings Limited (SEHK stock code: 00801) (“Golden Meditech” or the “Company”, together with its subsidiaries, the “Group”), a leading integrated healthcare enterprise in China, announces today its interim results for the six months ended 30 September 2019

ADVANZ PHARMA Corp. (“ADVANZ PHARMA” or “the Company”) (TSX:ADVZ), an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with enhanced access to high quality, niche-established medicines, today announced that it will hold a special meeting of shareholders on December 17, 2019, at 10:00 am

CTT Pharmaceutical Holdings, Inc., (the “Company” or “CTT”) (OTC: CTTH), an innovative life sciences company with a portfolio of IP in novel drug delivery systems, announced today several additions to its Board of Directors and management team

A live audio webcast of the presentations will be available on the Investors section of the company’s website, www.rocketpharma.com.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following presentations in December